Analyst Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on ACADIA Pharmaceuticals and keeping the price target at $31.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Hold rating due to a combination of factors related to both growth drivers and uncertainties around ACADIA’s portfolio. While Daybue’s U.S. launch is tracking in line with expectations and community uptake remains strong, the anticipated negative CHMP opinion in Europe and the need for re-examination create overhang on near-term ex-U.S. upside.
At the same time, Nuplazid’s recent sales fell short of consensus, even though management’s salesforce expansion and updated guidance point to improving trajectory and modest estimate increases. The upcoming Phase 2 readout for remlifanserin in Alzheimer’s psychosis offers meaningful optionality, but clinical and regulatory risk remain, and the stock already discounts a fair portion of this pipeline value, supporting a Neutral stance with a $31 price objective.
Ahmad covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Ocular Therapeutix. According to TipRanks, Ahmad has an average return of 0.9% and a 54.73% success rate on recommended stocks.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $25.00 price target.